adalimumab,upadacitinib,secukinumab
novartis,abbvie
['adalimumab', ' psa', 'ibd', 'inflammatory,bowel', 'axspa', 'secukinumab', ' upa ', 'psoriasis', 'emergent ']
#eular2023 clinical highlights. spa: op0059 h2h rct of sec vs ada biosimilar in bdmards naive showed no difference in imaging progression at 2yrs. op0061 pooled analyses of upa rcts showed low rates of extra-articular manifestation. numerically lower vs pbo for uveitis 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏